1984
DOI: 10.1093/ajcp/81.3.409
|View full text |Cite
|
Sign up to set email alerts
|

On Excluding Monoclonal Gammopathy

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

0
2
0

Year Published

1987
1987
1999
1999

Publication Types

Select...
2
1

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(2 citation statements)
references
References 0 publications
0
2
0
Order By: Relevance
“…Patients with the antiphospholipid syndrome (APS) suffer a thrombophilic condition characterized by multiple defects such as acquired deficiencies of protein C (PC), protein S (PS), and antithrombin III (AT III) (1); impaired fibrinolysis (2); increased levels of lipoprotein (a) (3); vasculopathy (4); activated PC resistance (5-7), etc. Some, but not all, of these changes have been related to the presence of antiphospholipid antibodies (APA), lupus anticoagulants (LAs), and autoantibodies directed towards PC (8); PS (9); AT III (10), tissue-type plasminogen activator (11), thrombomodulin (12), and other phospholipid-binding plasma proteins (13).…”
mentioning
confidence: 99%
See 1 more Smart Citation
“…Patients with the antiphospholipid syndrome (APS) suffer a thrombophilic condition characterized by multiple defects such as acquired deficiencies of protein C (PC), protein S (PS), and antithrombin III (AT III) (1); impaired fibrinolysis (2); increased levels of lipoprotein (a) (3); vasculopathy (4); activated PC resistance (5-7), etc. Some, but not all, of these changes have been related to the presence of antiphospholipid antibodies (APA), lupus anticoagulants (LAs), and autoantibodies directed towards PC (8); PS (9); AT III (10), tissue-type plasminogen activator (11), thrombomodulin (12), and other phospholipid-binding plasma proteins (13).…”
mentioning
confidence: 99%
“…Some, but not all, of these changes have been related to the presence of antiphospholipid antibodies (APA), lupus anticoagulants (LAs), and autoantibodies directed towards PC (8); PS (9); AT III (10), tissue-type plasminogen activator (11), thrombomodulin (12), and other phospholipid-binding plasma proteins (13). The APS may be associated with systemic lupus erythematosus (14)(15) or have no associated condition (primary APS) (16)(17).…”
mentioning
confidence: 99%